Some Common Dose-Exposure-Response Estimands and Conditions for Their Causal Identifiability.

Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE

Publication: 2015- : Hoboken, NJ : Wiley
Original Publication: New York, NY : Nature Pub. Group

Drug Development*/methods ; Dose-Response Relationship, Drug*; Humans ; Computer Simulation ; Models, Statistical

Exposure-response analyses are central to dose selection in drug development. The estimand framework, formalized in ICH E9(R1) regulatory guidance, provides a structured approach to define scientific objectives with precision. We apply the estimand framework to dose-exposure-response analyses. For simulated example studies inspired by real-world scenarios, we define dose-response estimands of clinical interest. The estimands are formalized using the potential outcome notation. Assumptions on the setup of the studies and the relation between treatment, exposure and response are expressed as a directed acyclic graph (DAG). The estimand is transformed using the assumption into expressions to identify the estimand based on the observed data. Three types of expressions are obtained. First, a pooled dose-exposure-response (DER) analysis that corresponds to a standard DER analysis as executed for many projects. Second, a pooled, covariate adjusted dose-response (DR) analysis, and third summaries of the outcomes in each randomized cohort. In our example, DER provides more precise estimates than DR as judged by the mean square error (MSE) of repeated simulation estimation. This work advances methodological rigor in DER analyses by integrating with causal inference methodologies and the estimand framework, enabling clearer interpretation of modeling assumptions and results. This has important concrete advantages. We obtain different estimation methods for the same estimand that may be compared to validate them. The potential for bias in the different estimation methods can be formally assessed. The proposed approach provides a generalizable strategy to improve exposure-response analyses for dose selection, particularly when the relevant evidence includes data from multiple studies.
(© 2026 The Author(s). CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)

JAMA Netw Open. 2023 Sep 5;6(9):e2336023. (PMID: 37755828)
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1641-1654. (PMID: 39077926)
CPT Pharmacometrics Syst Pharmacol. 2026 Feb;15(2):e70202. (PMID: 41612735)
JAMA. 2025 Aug 19;334(7):565-566. (PMID: 40493446)
Biometrics. 2023 Jun;79(2):1057-1072. (PMID: 35789478)
Health Psychol Rev. 2025 Mar;19(1):45-65. (PMID: 39327907)
CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):27-40. (PMID: 36385744)
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1655-1669. (PMID: 39155584)

Keywords: causal inference; dose‐finding; estimand framework; exposure–response; pharmacometrics; standardization

Date Created: 20260130 Date Completed: 20260130 Latest Revision: 20260202

20260202

PMC12856051

10.1002/psp4.70202

41612735